Skip to main content
TipRanks
Go Ultimate75% OFF

Solventum Corporation (SOLV) AI Stock Analysis

309 Followers
SOLV

Solventum Corporation

(NYSE:SOLV)

Select Model
Rating:52Neutral
Price Target:$88.00▼(-0.70% Downside)
Action:reiterated
Date:11/06/26

The score is held back primarily by weakened TTM profitability and especially poor recent free-cash-flow performance, alongside a moderate leverage profile. Offsetting factors include a constructive earnings-call update with raised EPS and margin outlook and generally neutral technicals, but the high P/E valuation limits upside confidence without clear, sustained earnings and cash-flow recovery.

Positive Factors
HIS Software GrowthHealth Information Systems is showing organic growth alongside strong customer retention and rising adoption of revenue-cycle and AI coding solutions. Continued use of these software offerings can deepen customer relationships, support recurring demand, and diversify Solventum beyond procedure-driven products.
Negative Factors
Profitability DeteriorationThe sharp decline in net and operating margins indicates that recent earnings power is substantially weaker than in prior years. Until profitability recovers consistently, Solventum may have less capacity to fund investment, absorb cost pressure, or convert revenue growth into durable shareholder returns.

Solventum Corporation Key Performance Indicators (KPIs)

Operating Income by SegmentReports profit after operating costs for each segment, showing which parts of Solventum generate the most earnings and where margins are under pressure. Comparing operating income across segments helps investors judge capital allocation, operational efficiency, and where management should prioritize improvements or investments.

-$1.00B-$500.00M$0.00$500.00M$1.00B$1.50BMar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Underlying segment profitability looks healthier than reported swings: Health Information Systems is the clear growth engine, MedSurg is drifting down modestly, Dental is stabilizing after SKU rationalization, and Purification & Filtration has been exited—explaining its disappearance and the large one‑time gain that produced the Corporate & Unallocated spike. Amortization pressure is easing. Management’s margin targets rely on Transform savings and HIS momentum, but ERP cutover and separation timing will keep quarter-to-quarter volatility elevated.

Data provided by:The Fly

Solventum Corporation (SOLV) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%SOLV+17.13%SPY+14.28%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$15.33B
Dividend Yield
―
Average Volume (3M)
1.07M
Price to Earnings (P/E)
99.6
Beta (1Y)
0.73
Revenue Growth
-3.09%
EPS Growth
-89.72%
Country
US
Employees
20,584
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Solventum Corporation Business Overview & Revenue Model

Company Description

Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patien...

How the Company Makes Money

Solventum makes money primarily by selling healthcare products and related solutions to providers and channel partners. Key revenue streams include: (1) consumable and procedure-driven medical products (e.g., medical/surgical supplies and solutions u...

Solventum Corporation Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:1.65%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentPositive

The call was predominantly positive. Management reported solid execution through a highly complex ERP cutover, raised full-year EPS and operating-margin expectations, advanced the 3M separation beyond 90%, improved the supply agreement outlook, and highlighted broad product and growth-driver momentum. The principal challenges were the ERP-related timing reversal, reported and segment-level sales declines, tariff and inflation headwinds, remaining separation work, and anticipated margin dilution from the HIS separation. Overall, the stated achievements and outlook significantly outweighed the disclosed challenges.

Positive Updates

ERP Cutover Completed Despite Operational Complexity
Solventum executed the largest and most complex ERP cutover in company history, completing all approximately 1,200 application system moves. Although the cutover was not seamless, management said its mitigation plan held, product continued moving to patients, and all key financial metrics were in line with or ahead of expectations, with organic growth and EPS above plan.

Negative Updates

Reported and Organic Sales Decline in Q3
Q3 reported sales decreased 7% to $1.95 billion, while organic sales decreased 2.8%. The organic decline included a $125 million reversal of ERP-related advanced orders, which represented an approximately 630 basis point headwind to organic sales growth.

Company Guidance

For 2026, Solventum expects organic sales growth toward the high end of its 2.5% to 3% range; excluding the expected 100 basis point impact for SKU exits this year, this would represent growth closer to 4%, with foreign currency exchange rates having a favorable impact of approximately 100 basis points on reported sales growth. Full year gross margins are expected to be approximately 57%, including 120 basis points annual margin benefit from the Q2 tariff refund, while operating margin is expected toward the high end of the previously raised 22.2% to 22.7% range, compared with the initial fiscal year outlook of 21% to 21.5% before adding 120 basis points for tariff refunds; excluding the tariff refund benefit, this indicates an expected 100 basis points of expansion over prior year. Annual nonoperating expense is expected to be approximately $300 million, the tax rate is expected to be 19.5% to 20.5%, earnings per share are expected to be $7.20 to $7.30 versus the prior range of $7.10 to $7.20, and free cash flow is expected to be $200 million to $300 million, with a large majority in the fourth quarter; excluding separation and portfolio-related costs, free cash flow is tracking to approximately $1 billion for 2026. For RemainCo, the aggregate market growth rate and existing long-range plan organic sales growth target remain 4% to 5%, while the HIS separation is expected to result in approximately 400 basis points of annualized net operating margin dilution after considering the anticipated benefit of transition service offsets in the short term.

Solventum Corporation Financial Statement Overview

Summary

Underlying fundamentals are mixed and currently pressured: profitability deteriorated sharply in the TTM period (net margin fell to ~2% after strong double-digits previously) and cash generation weakened materially (free cash flow near-zero/negative recently), creating quality-of-earnings and capital flexibility concerns. The balance sheet is manageable but not conservative, with moderate-to-elevated leverage.

Income Statement

52Neutral

Balance Sheet

60Neutral

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue8.16B8.32B8.25B8.20B8.13B8.17B
Gross Profit4.43B4.45B4.59B4.69B4.70B4.92B
EBITDA801.00M2.55B1.53B2.23B2.27B2.48B
Net Income156.00M1.56B479.00M1.35B1.34B1.46B
Balance Sheet
Total Assets14.16B14.29B14.46B13.94B13.59B14.07B
Cash, Cash Equivalents and Short-Term Investments451.00M878.00M762.00M194.00M61.00M91.00M
Total Debt5.27B5.04B8.01B8.30B95.00M112.00M
Total Liabilities9.36B9.24B11.50B2.28B1.85B2.02B
Stockholders Equity4.80B5.05B2.96B11.67B11.74B12.06B
Cash Flow
Free Cash Flow0-10.00M805.00M1.63B1.43B1.93B
Operating Cash Flow310.00M369.00M1.19B1.92B1.68B2.20B
Investing Cash Flow-989.00M2.80B-380.00M-230.00M-253.00M-278.00M
Financing Cash Flow-516.00M-3.06B-240.00M-1.55B-1.46B-1.96B

Solventum Corporation Technical Analysis

Technical Analysis SentimentPositive
Last Price88.62

Price Trends

50DMA87.65Positive
100DMA85.34Positive
200DMA78.72Positive

Market Momentum

MACD0.58Negative
RSI54.21Neutral
STOCH72.53Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SOLV, the sentiment is Positive. The current price of 88.62 is above the 20-day moving average (MA) of 86.29, above the 50-day MA of 87.65, and above the 200-day MA of 78.72, indicating a bullish trend. The MACD of 0.58 indicates Negative momentum. The RSI at 54.21 is Neutral, neither overbought nor oversold. The STOCH value of 72.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SOLV.

Solventum Corporation Risk Analysis

Solventum Corporation disclosed 42 risk factors in its most recent earnings report. Solventum Corporation reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Solventum's restructuring program may not be successful or Solventum may not fully realize the expected cost savings and/or operating efficiencies from its restructuring initiatives.Q4, 2025
2.Solventum may not be able to effectively integrate acquired businesses into its operations or achieve expected cost savings or profitability from its acquisitions.Q4, 2025
3.The deployment and use of artificial intelligence ("AI"), machine learning, or other emerging technologies in Solventum's products and services, including as part of its research and development efforts, or its failure to adapt its products or services to industry trends and developments related to such technologies in a timely manner, or at all, could adversely affect Solventum's business, financial condition, results of operations and cash flows.Q4, 2025

Solventum Corporation Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SOLV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
WSTWST78Outperform$28.74B46.0321.08%0.22%12.60%32.05%
AVTRAVTR66Neutral$10.55B31.385.96%―0.92%―
BDXBDX63Neutral$57.91B51.693.67%1.85%-7.40%-28.89%
TFXTFX57Neutral$6.16B18.799.74%0.87%-29.30%―
SOLVSOLV52Neutral$15.29B99.573.18%―-3.09%-89.72%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BAXBAX45Neutral$13.67B-19.09-11.62%0.15%5.33%-164.67%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%SOLVBAXBDXTFXWSTAVTRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SOLV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SOLVSolventum Corporation88.6213.4017.81%
BAXBaxter International Inc26.347.6841.13%
BDXBecton, Dickinson and Co214.5266.5244.95%
TFXTeleflex156.3348.1044.44%
WSTWest Pharmaceutical Services, Inc.412.86146.9955.28%
AVTRAvantor15.734.0334.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026